Literature DB >> 35337716

Psychosocial and behavioral therapy in conjunction with medication for opioid use disorder: Patterns, predictors, and association with buprenorphine treatment outcomes.

Hillary Samples1, Arthur Robin Williams2, Stephen Crystal3, Mark Olfson4.   

Abstract

INTRODUCTION: Current evidence indicates that buprenorphine is a highly effective treatment for opioid use disorder (OUD), though premature medication discontinuation is common. Research on concurrent psychosocial and behavioral therapy services and related outcomes is limited. The goal of this study was to define patterns of OUD-related psychosocial and behavioral therapy services received in the first 6 months after buprenorphine initiation, identify patients' characteristics associated with service patterns, and examine the course of buprenorphine treatment, including the association of therapy with medication treatment duration.
METHODS: We analyzed 2013-2018 MarketScan Multi-State Medicaid claims data. The sample included adults aged 18-64 years at buprenorphine initiation with treatment episodes of at least 7 days (n = 61,976). We used group-based trajectory models to define therapy service patterns and multinomial logistic regression to identify pre-treatment patient characteristics associated with therapy trajectories. Multinomial propensity-score weighted Cox proportional hazards regression estimated time to buprenorphine discontinuation and unweighted Cox proportional hazards models estimated risk of adverse health care events during buprenorphine treatment (all-cause and opioid-related inpatient and emergency department services, overdose treatment).
RESULTS: We identified three trajectories of psychosocial and behavioral therapy services: none (73.8%), low-intensity (17.2%), and high-intensity (9.0%). Compared to those without therapy, low-intensity and high-intensity service patterns were associated with behavioral health diagnoses and medical treatment for opioid overdose in the baseline period prior to buprenorphine initiation. The hazard of buprenorphine discontinuation was significantly lower for low-intensity (HR = 0.55; 95% CI, 0.54-0.57) and high-intensity (HR = 0.71; 95% CI, 0.67-0.74) therapy groups compared to those without therapy services. Yet patients in the high-intensity therapy group had increased risk of opioid-related health care events during buprenorphine treatment, including medical treatment for opioid overdose (HR = 1.29; 95% CI, 1.01-1.64).
CONCLUSION: Most patients received little or no OUD-related psychosocial and behavioral therapy after initiating buprenorphine treatment. Patients who received therapy had characteristics indicating greater treatment needs as well as more complex treatment courses. Concurrent therapy services may help to address premature buprenorphine discontinuation, particularly for patients with high-risk clinical profiles; however, future prospective research should determine whether therapy is effective for extending buprenorphine retention.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Buprenorphine; Medication for opioid use disorder; Opioid use disorder; Psychosocial services; Therapy

Mesh:

Substances:

Year:  2022        PMID: 35337716      PMCID: PMC9187597          DOI: 10.1016/j.jsat.2022.108774

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  29 in total

Review 1.  Retention in medication-assisted treatment for opiate dependence: A systematic review.

Authors:  Christine Timko; Nicole R Schultz; Michael A Cucciare; Lisa Vittorio; Christina Garrison-Diehn
Journal:  J Addict Dis       Date:  2015-10-14

2.  Outpatient care for opioid use disorder among the commercially insured: Use of medication and psychosocial treatment.

Authors:  Alisa B Busch; Shelly F Greenfield; Sharon Reif; Sharon-Lise T Normand; Haiden A Huskamp
Journal:  J Subst Abuse Treat       Date:  2020-05-22

Review 3.  Management of opioid use disorder in the USA: present status and future directions.

Authors:  Carlos Blanco; Nora D Volkow
Journal:  Lancet       Date:  2019-03-14       Impact factor: 79.321

4.  Treatment of Opioid Use Disorder Among Commercially Insured Patients in the Context of the COVID-19 Pandemic.

Authors:  Haiden A Huskamp; Alisa B Busch; Lori Uscher-Pines; Michael L Barnett; Lauren Riedel; Ateev Mehrotra
Journal:  JAMA       Date:  2020-12-15       Impact factor: 56.272

5.  Impact Of Long-Term Buprenorphine Treatment On Adverse Health Care Outcomes In Medicaid.

Authors:  Hillary Samples; Arthur Robin Williams; Stephen Crystal; Mark Olfson
Journal:  Health Aff (Millwood)       Date:  2020-05       Impact factor: 6.301

6.  Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.

Authors:  Hillary Samples; Arthur Robin Williams; Mark Olfson; Stephen Crystal
Journal:  J Subst Abuse Treat       Date:  2018-09-07

7.  Receipt of Timely Addiction Treatment and Association of Early Medication Treatment With Retention in Care Among Youths With Opioid Use Disorder.

Authors:  Scott E Hadland; Sarah M Bagley; Jonathan Rodean; Michael Silverstein; Sharon Levy; Marc R Larochelle; Jeffrey H Samet; Bonnie T Zima
Journal:  JAMA Pediatr       Date:  2018-11-01       Impact factor: 16.193

8.  Adjunct interventions to standard medical management of buprenorphine in outpatient settings: A systematic review of the evidence.

Authors:  Jessica J Wyse; Benjamin J Morasco; Jacob Dougherty; Beau Edwards; Devan Kansagara; Adam J Gordon; P Todd Korthuis; Anaïs Tuepker; Stephan Lindner; Katherine Mackey; Beth Williams; Anders Herreid-O'Neill; Robin Paynter; Travis I Lovejoy
Journal:  Drug Alcohol Depend       Date:  2021-07-29       Impact factor: 4.852

9.  Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder.

Authors:  Naoko A Ronquest; Tina M Willson; Leslie B Montejano; Vijay R Nadipelli; Bernd A Wollschlaeger
Journal:  Subst Abuse Rehabil       Date:  2018-09-21

10.  The provision of counseling to patients receiving medications for opioid use disorder: Telehealth innovations and challenges in the age of COVID-19.

Authors:  Jaclyn M W Hughto; Lisa Peterson; Nicholas S Perry; Alex Donoyan; Matthew J Mimiaga; Kimberly M Nelson; David W Pantalone
Journal:  J Subst Abuse Treat       Date:  2020-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.